Ineffectiveness of pioglitazone in cognitive impairment induced by cyclophosphamide, methotrexate, and fluorouracil via oxidative stress and neuroinflammation Article Swipe
Research objective Chemotherapy is frequently linked to enduring cognitive impairments in individuals who have survived cancer. The cyclophosphamide, methotrexate, and fluorouracil (CMF) regimen is a standard protocol in cancer treatment. Pioglitazone (PGZ), an oral medication used to treat diabetes, has demonstrated neuroprotective effects against certain chemotherapeutic agents, such as doxorubicin. This study aimed to evaluate the efficacy of PGZ in mitigating cognitive dysfunction caused by CMF. Materials and methods Forty male rats were allocated into four distinct groups: control, CMF-treated, PGZ-treated, and CMF + PGZ-treated, to evaluate survival rates, body weights, and cognitive performance using the Y-maze, novel object recognition test (NORT), and fear conditioning memory assessments. Furthermore, the investigation included an analysis of mitochondrial complex I activity, reactive oxygen species (ROS), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) within the hippocampus. Results The CMF and CMF + PGZ groups exhibited decreased survival rates (50 and 40%, respectively) and reductions in body weight (16 and 11%, respectively). The Y-maze showed fewer entries and less time in the novel arm, but total entries were unchanged. The NORT revealed less exploration of the novel object in both CMF and CMF + PGZ groups. In fear conditioning, both groups showed reduced freezing time versus control, indicating memory impairment. Furthermore, mitochondrial complex I activity was diminished, and levels of ROS, TNF-α, and IL-1β were elevated in CMF; however, co-treatment with PGZ did not ameliorate these alterations. Conclusion The CMF treatment resulted in cognitive dysfunction, and the addition of PGZ did not alleviate this neurotoxicity.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3389/fnins.2025.1648041
- https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1648041/pdf
- OA Status
- gold
- References
- 39
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4413998560
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4413998560Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3389/fnins.2025.1648041Digital Object Identifier
- Title
-
Ineffectiveness of pioglitazone in cognitive impairment induced by cyclophosphamide, methotrexate, and fluorouracil via oxidative stress and neuroinflammationWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-09-04Full publication date if available
- Authors
-
Ahmad AlhowailList of authors in order
- Landing page
-
https://doi.org/10.3389/fnins.2025.1648041Publisher landing page
- PDF URL
-
https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1648041/pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1648041/pdfDirect OA link when available
- Concepts
-
Neuroinflammation, Pioglitazone, Oxidative stress, Methotrexate, Cyclophosphamide, Cognitive impairment, Medicine, Pharmacology, Internal medicine, Cognition, Inflammation, Endocrinology, Chemotherapy, Psychiatry, Diabetes mellitus, Type 2 diabetesTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
39Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4413998560 |
|---|---|
| doi | https://doi.org/10.3389/fnins.2025.1648041 |
| ids.doi | https://doi.org/10.3389/fnins.2025.1648041 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40979534 |
| ids.openalex | https://openalex.org/W4413998560 |
| fwci | 0.0 |
| type | article |
| title | Ineffectiveness of pioglitazone in cognitive impairment induced by cyclophosphamide, methotrexate, and fluorouracil via oxidative stress and neuroinflammation |
| biblio.issue | |
| biblio.volume | 19 |
| biblio.last_page | 1648041 |
| biblio.first_page | 1648041 |
| topics[0].id | https://openalex.org/T13077 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Cancer-related cognitive impairment studies |
| topics[1].id | https://openalex.org/T10009 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9645000100135803 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2738 |
| topics[1].subfield.display_name | Psychiatry and Mental health |
| topics[1].display_name | Dementia and Cognitive Impairment Research |
| topics[2].id | https://openalex.org/T10129 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9427000284194946 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2716 |
| topics[2].subfield.display_name | Genetics |
| topics[2].display_name | Glioma Diagnosis and Treatment |
| is_xpac | False |
| apc_list.value | 2950 |
| apc_list.currency | USD |
| apc_list.value_usd | 2950 |
| apc_paid.value | 2950 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2950 |
| concepts[0].id | https://openalex.org/C87753298 |
| concepts[0].level | 3 |
| concepts[0].score | 0.836654782295227 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q17157137 |
| concepts[0].display_name | Neuroinflammation |
| concepts[1].id | https://openalex.org/C2778384471 |
| concepts[1].level | 4 |
| concepts[1].score | 0.8326330780982971 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q417765 |
| concepts[1].display_name | Pioglitazone |
| concepts[2].id | https://openalex.org/C2776151105 |
| concepts[2].level | 2 |
| concepts[2].score | 0.7882862091064453 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q898814 |
| concepts[2].display_name | Oxidative stress |
| concepts[3].id | https://openalex.org/C2781059491 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6140025854110718 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q422232 |
| concepts[3].display_name | Methotrexate |
| concepts[4].id | https://openalex.org/C2776755627 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5790726542472839 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q408524 |
| concepts[4].display_name | Cyclophosphamide |
| concepts[5].id | https://openalex.org/C2984915365 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5676597356796265 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q5141203 |
| concepts[5].display_name | Cognitive impairment |
| concepts[6].id | https://openalex.org/C71924100 |
| concepts[6].level | 0 |
| concepts[6].score | 0.5180556774139404 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[6].display_name | Medicine |
| concepts[7].id | https://openalex.org/C98274493 |
| concepts[7].level | 1 |
| concepts[7].score | 0.39009982347488403 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[7].display_name | Pharmacology |
| concepts[8].id | https://openalex.org/C126322002 |
| concepts[8].level | 1 |
| concepts[8].score | 0.3497541546821594 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[8].display_name | Internal medicine |
| concepts[9].id | https://openalex.org/C169900460 |
| concepts[9].level | 2 |
| concepts[9].score | 0.34683334827423096 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q2200417 |
| concepts[9].display_name | Cognition |
| concepts[10].id | https://openalex.org/C2776914184 |
| concepts[10].level | 2 |
| concepts[10].score | 0.23932281136512756 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q101991 |
| concepts[10].display_name | Inflammation |
| concepts[11].id | https://openalex.org/C134018914 |
| concepts[11].level | 1 |
| concepts[11].score | 0.17832928895950317 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[11].display_name | Endocrinology |
| concepts[12].id | https://openalex.org/C2776694085 |
| concepts[12].level | 2 |
| concepts[12].score | 0.17328152060508728 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[12].display_name | Chemotherapy |
| concepts[13].id | https://openalex.org/C118552586 |
| concepts[13].level | 1 |
| concepts[13].score | 0.09225454926490784 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q7867 |
| concepts[13].display_name | Psychiatry |
| concepts[14].id | https://openalex.org/C555293320 |
| concepts[14].level | 2 |
| concepts[14].score | 0.09107166528701782 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q12206 |
| concepts[14].display_name | Diabetes mellitus |
| concepts[15].id | https://openalex.org/C2777180221 |
| concepts[15].level | 3 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q3025883 |
| concepts[15].display_name | Type 2 diabetes |
| keywords[0].id | https://openalex.org/keywords/neuroinflammation |
| keywords[0].score | 0.836654782295227 |
| keywords[0].display_name | Neuroinflammation |
| keywords[1].id | https://openalex.org/keywords/pioglitazone |
| keywords[1].score | 0.8326330780982971 |
| keywords[1].display_name | Pioglitazone |
| keywords[2].id | https://openalex.org/keywords/oxidative-stress |
| keywords[2].score | 0.7882862091064453 |
| keywords[2].display_name | Oxidative stress |
| keywords[3].id | https://openalex.org/keywords/methotrexate |
| keywords[3].score | 0.6140025854110718 |
| keywords[3].display_name | Methotrexate |
| keywords[4].id | https://openalex.org/keywords/cyclophosphamide |
| keywords[4].score | 0.5790726542472839 |
| keywords[4].display_name | Cyclophosphamide |
| keywords[5].id | https://openalex.org/keywords/cognitive-impairment |
| keywords[5].score | 0.5676597356796265 |
| keywords[5].display_name | Cognitive impairment |
| keywords[6].id | https://openalex.org/keywords/medicine |
| keywords[6].score | 0.5180556774139404 |
| keywords[6].display_name | Medicine |
| keywords[7].id | https://openalex.org/keywords/pharmacology |
| keywords[7].score | 0.39009982347488403 |
| keywords[7].display_name | Pharmacology |
| keywords[8].id | https://openalex.org/keywords/internal-medicine |
| keywords[8].score | 0.3497541546821594 |
| keywords[8].display_name | Internal medicine |
| keywords[9].id | https://openalex.org/keywords/cognition |
| keywords[9].score | 0.34683334827423096 |
| keywords[9].display_name | Cognition |
| keywords[10].id | https://openalex.org/keywords/inflammation |
| keywords[10].score | 0.23932281136512756 |
| keywords[10].display_name | Inflammation |
| keywords[11].id | https://openalex.org/keywords/endocrinology |
| keywords[11].score | 0.17832928895950317 |
| keywords[11].display_name | Endocrinology |
| keywords[12].id | https://openalex.org/keywords/chemotherapy |
| keywords[12].score | 0.17328152060508728 |
| keywords[12].display_name | Chemotherapy |
| keywords[13].id | https://openalex.org/keywords/psychiatry |
| keywords[13].score | 0.09225454926490784 |
| keywords[13].display_name | Psychiatry |
| keywords[14].id | https://openalex.org/keywords/diabetes-mellitus |
| keywords[14].score | 0.09107166528701782 |
| keywords[14].display_name | Diabetes mellitus |
| language | en |
| locations[0].id | doi:10.3389/fnins.2025.1648041 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S115201632 |
| locations[0].source.issn | 1662-453X, 1662-4548 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1662-453X |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Frontiers in Neuroscience |
| locations[0].source.host_organization | https://openalex.org/P4310320527 |
| locations[0].source.host_organization_name | Frontiers Media |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320527 |
| locations[0].source.host_organization_lineage_names | Frontiers Media |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1648041/pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Frontiers in Neuroscience |
| locations[0].landing_page_url | https://doi.org/10.3389/fnins.2025.1648041 |
| locations[1].id | pmid:40979534 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Frontiers in neuroscience |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40979534 |
| locations[2].id | pmh:oai:doaj.org/article:3e0422402159466d85169e0bf69d6672 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Frontiers in Neuroscience, Vol 19 (2025) |
| locations[2].landing_page_url | https://doaj.org/article/3e0422402159466d85169e0bf69d6672 |
| locations[3].id | pmh:oai:europepmc.org:11253369 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306400806 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Europe PMC (PubMed Central) |
| locations[3].source.host_organization | https://openalex.org/I1303153112 |
| locations[3].source.host_organization_name | European Bioinformatics Institute |
| locations[3].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12443734 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5009055174 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-1427-032X |
| authorships[0].author.display_name | Ahmad Alhowail |
| authorships[0].countries | SA |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I156216236 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraidah, Saudi Arabia |
| authorships[0].institutions[0].id | https://openalex.org/I156216236 |
| authorships[0].institutions[0].ror | https://ror.org/01wsfe280 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I156216236 |
| authorships[0].institutions[0].country_code | SA |
| authorships[0].institutions[0].display_name | Qassim University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Ahmad Hamad Alhowail |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraidah, Saudi Arabia |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1648041/pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Ineffectiveness of pioglitazone in cognitive impairment induced by cyclophosphamide, methotrexate, and fluorouracil via oxidative stress and neuroinflammation |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T13077 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Cancer-related cognitive impairment studies |
| related_works | https://openalex.org/W3142910047, https://openalex.org/W2471768190, https://openalex.org/W1967713685, https://openalex.org/W2057743727, https://openalex.org/W46097970, https://openalex.org/W2254484345, https://openalex.org/W2422194403, https://openalex.org/W2401374230, https://openalex.org/W2073777794, https://openalex.org/W1571365261 |
| cited_by_count | 0 |
| locations_count | 4 |
| best_oa_location.id | doi:10.3389/fnins.2025.1648041 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S115201632 |
| best_oa_location.source.issn | 1662-453X, 1662-4548 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1662-453X |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Frontiers in Neuroscience |
| best_oa_location.source.host_organization | https://openalex.org/P4310320527 |
| best_oa_location.source.host_organization_name | Frontiers Media |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| best_oa_location.source.host_organization_lineage_names | Frontiers Media |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1648041/pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Frontiers in Neuroscience |
| best_oa_location.landing_page_url | https://doi.org/10.3389/fnins.2025.1648041 |
| primary_location.id | doi:10.3389/fnins.2025.1648041 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S115201632 |
| primary_location.source.issn | 1662-453X, 1662-4548 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1662-453X |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Frontiers in Neuroscience |
| primary_location.source.host_organization | https://openalex.org/P4310320527 |
| primary_location.source.host_organization_name | Frontiers Media |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| primary_location.source.host_organization_lineage_names | Frontiers Media |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1648041/pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Frontiers in Neuroscience |
| primary_location.landing_page_url | https://doi.org/10.3389/fnins.2025.1648041 |
| publication_date | 2025-09-04 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W2521392361, https://openalex.org/W2926290865, https://openalex.org/W4210353574, https://openalex.org/W4387576482, https://openalex.org/W4386814564, https://openalex.org/W4389200852, https://openalex.org/W4293685719, https://openalex.org/W4224243503, https://openalex.org/W4380995312, https://openalex.org/W4381429871, https://openalex.org/W4221040717, https://openalex.org/W4400960579, https://openalex.org/W4323928905, https://openalex.org/W2106847574, https://openalex.org/W3195190303, https://openalex.org/W3005664296, https://openalex.org/W2895587415, https://openalex.org/W4377107792, https://openalex.org/W4324352689, https://openalex.org/W2609465808, https://openalex.org/W4377019682, https://openalex.org/W3012431228, https://openalex.org/W4386518398, https://openalex.org/W4408137451, https://openalex.org/W2168711831, https://openalex.org/W4367309650, https://openalex.org/W2989643829, https://openalex.org/W2780514589, https://openalex.org/W1598044456, https://openalex.org/W2913006758, https://openalex.org/W3193866691, https://openalex.org/W3167157652, https://openalex.org/W2921591094, https://openalex.org/W3122254526, https://openalex.org/W2904352548, https://openalex.org/W4302762778, https://openalex.org/W2938196301, https://openalex.org/W3152612895, https://openalex.org/W4298564356 |
| referenced_works_count | 39 |
| abstract_inverted_index.+ | 83, 137, 188 |
| abstract_inverted_index.I | 116, 208 |
| abstract_inverted_index.a | 24 |
| abstract_inverted_index.In | 191 |
| abstract_inverted_index.an | 32, 111 |
| abstract_inverted_index.as | 48 |
| abstract_inverted_index.by | 64 |
| abstract_inverted_index.in | 10, 27, 59, 150, 165, 183, 221, 237 |
| abstract_inverted_index.is | 3, 23 |
| abstract_inverted_index.of | 57, 113, 179, 214, 243 |
| abstract_inverted_index.to | 6, 36, 53, 85 |
| abstract_inverted_index.(16 | 153 |
| abstract_inverted_index.(50 | 144 |
| abstract_inverted_index.CMF | 82, 134, 136, 185, 187, 234 |
| abstract_inverted_index.PGZ | 58, 138, 189, 226, 244 |
| abstract_inverted_index.The | 16, 133, 157, 174, 233 |
| abstract_inverted_index.and | 19, 67, 81, 91, 102, 126, 135, 145, 148, 154, 162, 186, 212, 217, 240 |
| abstract_inverted_index.but | 169 |
| abstract_inverted_index.did | 227, 245 |
| abstract_inverted_index.has | 39 |
| abstract_inverted_index.not | 228, 246 |
| abstract_inverted_index.the | 55, 95, 108, 130, 166, 180, 241 |
| abstract_inverted_index.was | 210 |
| abstract_inverted_index.who | 12 |
| abstract_inverted_index.11%, | 155 |
| abstract_inverted_index.40%, | 146 |
| abstract_inverted_index.CMF. | 65 |
| abstract_inverted_index.CMF; | 222 |
| abstract_inverted_index.NORT | 175 |
| abstract_inverted_index.ROS, | 215 |
| abstract_inverted_index.This | 50 |
| abstract_inverted_index.arm, | 168 |
| abstract_inverted_index.body | 89, 151 |
| abstract_inverted_index.both | 184, 194 |
| abstract_inverted_index.fear | 103, 192 |
| abstract_inverted_index.four | 75 |
| abstract_inverted_index.have | 13 |
| abstract_inverted_index.into | 74 |
| abstract_inverted_index.less | 163, 177 |
| abstract_inverted_index.male | 70 |
| abstract_inverted_index.oral | 33 |
| abstract_inverted_index.rats | 71 |
| abstract_inverted_index.such | 47 |
| abstract_inverted_index.test | 100 |
| abstract_inverted_index.this | 248 |
| abstract_inverted_index.time | 164, 199 |
| abstract_inverted_index.used | 35 |
| abstract_inverted_index.were | 72, 172, 219 |
| abstract_inverted_index.with | 225 |
| abstract_inverted_index.(CMF) | 21 |
| abstract_inverted_index.Forty | 69 |
| abstract_inverted_index.aimed | 52 |
| abstract_inverted_index.fewer | 160 |
| abstract_inverted_index.novel | 97, 167, 181 |
| abstract_inverted_index.rates | 143 |
| abstract_inverted_index.study | 51 |
| abstract_inverted_index.these | 230 |
| abstract_inverted_index.total | 170 |
| abstract_inverted_index.treat | 37 |
| abstract_inverted_index.tumor | 122 |
| abstract_inverted_index.using | 94 |
| abstract_inverted_index.(PGZ), | 31 |
| abstract_inverted_index.(ROS), | 121 |
| abstract_inverted_index.IL-1β | 218 |
| abstract_inverted_index.Y-maze | 158 |
| abstract_inverted_index.cancer | 28 |
| abstract_inverted_index.caused | 63 |
| abstract_inverted_index.groups | 139, 195 |
| abstract_inverted_index.levels | 213 |
| abstract_inverted_index.linked | 5 |
| abstract_inverted_index.memory | 105, 203 |
| abstract_inverted_index.object | 98, 182 |
| abstract_inverted_index.oxygen | 119 |
| abstract_inverted_index.rates, | 88 |
| abstract_inverted_index.showed | 159, 196 |
| abstract_inverted_index.versus | 200 |
| abstract_inverted_index.weight | 152 |
| abstract_inverted_index.within | 129 |
| abstract_inverted_index.(NORT), | 101 |
| abstract_inverted_index.Results | 132 |
| abstract_inverted_index.TNF-α, | 216 |
| abstract_inverted_index.Y-maze, | 96 |
| abstract_inverted_index.against | 43 |
| abstract_inverted_index.agents, | 46 |
| abstract_inverted_index.cancer. | 15 |
| abstract_inverted_index.certain | 44 |
| abstract_inverted_index.complex | 115, 207 |
| abstract_inverted_index.effects | 42 |
| abstract_inverted_index.entries | 161, 171 |
| abstract_inverted_index.groups. | 190 |
| abstract_inverted_index.groups: | 77 |
| abstract_inverted_index.methods | 68 |
| abstract_inverted_index.reduced | 197 |
| abstract_inverted_index.regimen | 22 |
| abstract_inverted_index.species | 120 |
| abstract_inverted_index.(IL-1β) | 128 |
| abstract_inverted_index.Research | 0 |
| abstract_inverted_index.activity | 209 |
| abstract_inverted_index.addition | 242 |
| abstract_inverted_index.analysis | 112 |
| abstract_inverted_index.control, | 78, 201 |
| abstract_inverted_index.distinct | 76 |
| abstract_inverted_index.efficacy | 56 |
| abstract_inverted_index.elevated | 220 |
| abstract_inverted_index.enduring | 7 |
| abstract_inverted_index.evaluate | 54, 86 |
| abstract_inverted_index.freezing | 198 |
| abstract_inverted_index.however, | 223 |
| abstract_inverted_index.included | 110 |
| abstract_inverted_index.necrosis | 123 |
| abstract_inverted_index.protocol | 26 |
| abstract_inverted_index.reactive | 118 |
| abstract_inverted_index.resulted | 236 |
| abstract_inverted_index.revealed | 176 |
| abstract_inverted_index.standard | 25 |
| abstract_inverted_index.survival | 87, 142 |
| abstract_inverted_index.survived | 14 |
| abstract_inverted_index.weights, | 90 |
| abstract_inverted_index.(TNF-α), | 125 |
| abstract_inverted_index.Materials | 66 |
| abstract_inverted_index.activity, | 117 |
| abstract_inverted_index.alleviate | 247 |
| abstract_inverted_index.allocated | 73 |
| abstract_inverted_index.cognitive | 8, 61, 92, 238 |
| abstract_inverted_index.decreased | 141 |
| abstract_inverted_index.diabetes, | 38 |
| abstract_inverted_index.exhibited | 140 |
| abstract_inverted_index.factor-α | 124 |
| abstract_inverted_index.objective | 1 |
| abstract_inverted_index.treatment | 235 |
| abstract_inverted_index.Conclusion | 232 |
| abstract_inverted_index.ameliorate | 229 |
| abstract_inverted_index.frequently | 4 |
| abstract_inverted_index.indicating | 202 |
| abstract_inverted_index.medication | 34 |
| abstract_inverted_index.mitigating | 60 |
| abstract_inverted_index.reductions | 149 |
| abstract_inverted_index.treatment. | 29 |
| abstract_inverted_index.unchanged. | 173 |
| abstract_inverted_index.diminished, | 211 |
| abstract_inverted_index.dysfunction | 62 |
| abstract_inverted_index.exploration | 178 |
| abstract_inverted_index.impairment. | 204 |
| abstract_inverted_index.impairments | 9 |
| abstract_inverted_index.individuals | 11 |
| abstract_inverted_index.performance | 93 |
| abstract_inverted_index.recognition | 99 |
| abstract_inverted_index.CMF-treated, | 79 |
| abstract_inverted_index.Chemotherapy | 2 |
| abstract_inverted_index.Furthermore, | 107, 205 |
| abstract_inverted_index.PGZ-treated, | 80, 84 |
| abstract_inverted_index.Pioglitazone | 30 |
| abstract_inverted_index.alterations. | 231 |
| abstract_inverted_index.assessments. | 106 |
| abstract_inverted_index.co-treatment | 224 |
| abstract_inverted_index.conditioning | 104 |
| abstract_inverted_index.demonstrated | 40 |
| abstract_inverted_index.doxorubicin. | 49 |
| abstract_inverted_index.dysfunction, | 239 |
| abstract_inverted_index.fluorouracil | 20 |
| abstract_inverted_index.hippocampus. | 131 |
| abstract_inverted_index.conditioning, | 193 |
| abstract_inverted_index.investigation | 109 |
| abstract_inverted_index.methotrexate, | 18 |
| abstract_inverted_index.mitochondrial | 114, 206 |
| abstract_inverted_index.respectively) | 147 |
| abstract_inverted_index.neurotoxicity. | 249 |
| abstract_inverted_index.respectively). | 156 |
| abstract_inverted_index.interleukin-1β | 127 |
| abstract_inverted_index.neuroprotective | 41 |
| abstract_inverted_index.chemotherapeutic | 45 |
| abstract_inverted_index.cyclophosphamide, | 17 |
| cited_by_percentile_year | |
| corresponding_author_ids | https://openalex.org/A5009055174 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 1 |
| corresponding_institution_ids | https://openalex.org/I156216236 |
| citation_normalized_percentile.value | 0.54252563 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |